2nd edition.
The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide
Blueprint for EECA countries, first edition
There are social and environmental barriers faced by persons with disabilities which have been reported in literature. In discussing these barriers, attention is yet to be given to the support from families to members with disabilities. This study aimed to examine family support and its impact on th...e lives of persons with disabilities in Ghana.
more
Scientific advice
Prevention and control of communicable diseases in prison settings.
Key populations brief
Accessed November 2017
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...ce of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
Practical Guidance for collaborative interventions
Global HIV Strategic Information Working Group
For Populations At Risk For HIV